THE ROLE OF SPECIFIC KRAS MUTATION TYPES IN RESPONSE TO TREATMENT BY EGFR INHIBITORS

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F10%3A%230000095" target="_blank" >RIV/26475821:_____/10:#0000095 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

THE ROLE OF SPECIFIC KRAS MUTATION TYPES IN RESPONSE TO TREATMENT BY EGFR INHIBITORS

Original language description

KRAS mutations can be found in 15 to 25% of lung cancers, frequently in adenocarcinomas and their presence is associated with smoking. The role of KRAS mutations in biological targeted therapy by EGFR inhibitors is ambiguous. While some reports clearly assigned mutated KRAS as negative prognostic factor and negative predictor, others did not confirm such notion. In our work we aimed to elucidate the role of specific type of KRAS mutation in outcome of patients with advanced NSCLC threated with EGFR-TKItherapy.

Czech name

—

Czech description

—

Type

A - Audiovisual production

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NR9087" target="_blank" >NR9087: Use of molecular predictors for optimum selection of targeted therapy of non-small cell lung cancer</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>O - Projekt operacniho programu

Publication year

2010

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

ISBN

—

Place of publication

—

Publisher/client name

—

Version

—

Carrier ID

—